Tubo-ovarian carcinoma remains a leading cause of gynaecological-related mortality and continues to lack robust preclinical models that accurately reflect its biological heterogeneity. Through a joint effort between Gulbenkian Institute of Molecular Medicine and CUF Descobertas Hospital, the research team established patient-derived organoids from high- and low-grade serous carcinoma, as well as normal fallopian tube. Despite the limited cohort, the organoids preserved the morphological and immunophenotypical features of the original tissues.
